News

The biosimilars month in review highlights new approvals, new safety findings, and new cost savings with biosimilars.

This interview following Fall Clinical highlights new phase 3 data on patient-reported outcomes from the ARRECTOR study evaluating roflumilast foam for psoriasis.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

This conference review highlights several of the most notable stories and recent data covered by HCPLive at the Fall Clinical Dermatology Conference.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

Anthony Kerbage, MD, describes disparities in 21 IBS clinical trials whose data was used to support the FDA approvals of 7 IBS-C and IBS-D drugs.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

Mice models had improved disease phenotype and high transduction of PS-002 gene therapy.

T-VASI and F-VASI are validated, responsive tools for assessing vitiligo severity and re-pigmentation, with meaningful change thresholds established.

Mohammad Abuassi, MD, explains how classifying IBS based on triggers can aid the development of effective, personalized approaches to management.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

Yee discussed research she is conducting into gFSGS and nephrotic syndrome, presented at ASN Kidney Week.

These data suggest brodalumab’s safety profile is consistent with findings from long-term clinical trials, with no new occurrences of suicide and a low rate of fungal infection.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.

Abdellatif discussed the high prevalence of gout in patients with chronic kidney disease and the importance of screening and early treatment.

Open-label, interim data from ASSURE shows positive effect and tolerability with once-daily seladelpar in patients with primary biliary cholangitis and compensated cirrhosis.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.

Rao explains the comparative effectiveness of biofeedback and dextranomer injections for treating fecal incontinence.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.

In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.